SCHEMBL1491946

SCHEMBL1491946

COc1ccc(O[C@H]2O[C@H](C)[C@H](O)[C@H](OCc3ccccc3)[C@H]2OC(=O)CCC(C)=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGF2 P09038 1/20 0.44
MDK P21741 1/20 0.44
LGALS8 O00214 2/20 0.38
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 4/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2C19 P33261 4/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 2/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
TACR1 P25103 1/20 0.33
HPGD P15428 1/20 0.33
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1491923 0.86 FGF2 (0.43) FGF2MDKLGALS8NPC1RAB9A
SCHEMBL1491868 0.84 LGALS8 (0.40) LGALS8NPC1RAB9AALDH1A1CYP3A4
SCHEMBL1491891 0.81 CYP3A4 (0.41) LGALS8NPC1RAB9AALDH1A1CYP3A4
SCHEMBL15654703 0.79 FGF2 (0.39) FGF2MDKLGALS8NPC1RAB9A
SCHEMBL2469248 0.78 LGALS8 (0.35) LGALS8ALDH1A1CYP2C19CYP2C9TP53
SCHEMBL14672600 0.77 FGF2 (0.42) FGF2MDKNPC1RAB9ATP53
SCHEMBL1491873 0.77 SLC5A2 (0.42) NPC1RAB9ACYP3A4CYP2D6TACR1
SCHEMBL8401392 0.77 SMN1; SMN2 (0.43) LGALS8NPC1RAB9AALDH1A1CYP3A4
SCHEMBL1971069 0.75 PDPK1 (0.39) FGF2MDKLGALS8ALDH1A1CYP2C19
SCHEMBL15481391 0.74 LGALS3 (0.50) FGF2MDKLGALS8NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7901687-B2 Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections ETH ZURICH (CH) 2011-03-08 US disclosed
US-20090155299-A1 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections SCHWEIZERISCHES TROPENINSTITUT (CH) 2009-06-18 US disclosed
EP-2012821-A2 ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS ETH Zürich (CH) 2009-01-14 EP disclosed
WO-2007125089-A2 ANTIBODIES FOR THE DETECTION OF BACILLUS ANTHRACIS AND VACCINE AGAINST B. ANTHRACIS INFECTIONS ETH Zürich (CH) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155299-A1 Antibodies for the Detection of Bacillus Anthracis and Vaccine Against B. Anthracis Infections ANTXR2, CERT1, DAD1 FGF2 2980/4885MDK 3902/4885LGALS8 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.